GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK plc

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Acerta Pharma, an affiliate of AstraZeneca, develops and delivers targeted novel transformational medicines for patients with hematological malignancies.  Acerta Pharma uses innovative approaches to discover, develop, and deliver targeted medicines, focusing on innovative clinical strategies and resistance biology.

Acerta Pharma

AI in Pharma: Discovery is focused on exploring the applications of AI-based technology in drug discovery and development, specifically how AI, ML, NLP, data science, and generative deep learning models can optimize the pharmaceutical and biotechnology industries.

Metric
Company Name	GSK plc	LégiaPark	Acerta Pharma	AI in Pharma: Discovery
Symbol	GSK
MSH ID	COM:GSK	BE:LEGIAPARK	COM:ACERTA-PHARMA	COM:AIINPHARMA-DISCOVERY
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Life Sciences	Pharmaceutical	Pharmaceuticals
Country	GB	BE	NL	US
Stage
Employee Count	70.21K
Website	gsk.com	legiapark.be	acerta-pharma.com	aiinpharma-discovery.com
LinkedIn		l%C3%A9giapark
Founders

Metric
Market Cap	773.07M
Enterprise Value
Monthly Web Traffic	1.33M
Web Traffic Growth	0.02
Valuation
Raised Capital

Metric
Revenue	38.33B
Revenue (LTM)
Revenue (NTM)
Gross Profit	26.86B
EBITDA	11.74B
Operating Income	8.84B
Net Income	6.23B
EPS	1.54
Diluted EPS	1.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.73
Operating Profit Margin	0.26
EBITDA Margin	0.31
Net Profit Margin	0.16
Return on Equity	0.39
Return on Assets	0.08
Return on Capital Employed	0.20

COM:GSK

GSK plc

Last Close

1,342.00

25/11 09:24

Market Cap

617.02M

Beta: -

Volume Today

577.46K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	11.10
P/B Ratio	5.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.37
EV Multiple	5.83

Metric
Days Sales Outstanding
Days Payables Outstanding	678.29
Days Inventory Outstanding	247.86
Operating Cycle	338.14
Cash Conversion Cycle	-264.26
Asset Turnover	0.54

Metric
Operating Cash Flow	8.02B
Free Cash Flow	5.06B
Cash Flow to Debt	0.42
Operating Cash Flow/Sales	0.24
Free Cash Flow Yield	0.05

Metric
Cash & Equivalents	3.71B
Accounts Receivable	-820.34M
Inventory	6.95B
Goodwill	8.61B
Debt to Capitalization	0.56
Debt to Assets	0.34
Current Ratio	0.95
Quick Ratio	0.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.20
SG&A to Revenue	0.31